Literature DB >> 1642133

Urinary excretion of albumin and retinol-binding protein in lithium-treated patients: a longitudinal study.

H V Jensen1, L Hemmingsen, J Holm, E M Christensen, H Aggernaes.   

Abstract

The urinary excretion of albumin and retinol-binding protein was determined by means of sensitive immunochemical methods in a 2-year longitudinal study of 22 lithium-treated patients. During lithium treatment, there were no significant changes in the median albumin:creatinine ratios or retinol-binding protein:creatinine ratios. However, the median albumin:creatinine ratios were significantly higher in lithium-treated patients than in 22 normal subjects, which indicates that glomerular permeability is increased; no correlation with serum lithium level or duration of lithium treatment could be shown. In patients treated with slow-release tablets, the urinary excretion of albumin was significantly higher after 2 years than in patients given lithium carbonate. The median retinol-binding protein:creatinine ratios did not differ significantly between lithium-treated patients and normal subjects, suggesting that lithium does not affect the catabolism of low-molecular-weight proteins in the proximal tubules. In conclusion, the study supports the hypothesis that lithium treatment produces a small but significant and nonprogressive elevation of the urinary excretion of albumin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642133     DOI: 10.1111/j.1600-0447.1992.tb03215.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  2 in total

1.  Elevated urinary ADAM12 protein levels in lithium-treated bipolar patients.

Authors:  C Nadri; Y Bersudsky; R H Belmaker; G Agam
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

2.  Urinary excretion of albumin and transferrin in lithium maintenance treatment: daily versus alternate-day lithium dosing schedule.

Authors:  H V Jensen; J Holm; K Davidsen; L Toftegaard; H Aggernaes; N Bjørum
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.